Drug Approval | December 01, 2022
JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
This product is based on Osmotic Controlled Release Oral Delivery System technology
This product is based on Osmotic Controlled Release Oral Delivery System technology
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
The ANDA was filed as 'First to File' submission on NCE-1 date.
Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated
